查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298391

肌萎縮側索硬化症治療市場：按藥物、類型和分銷渠道劃分：2023-2032 年全球機會分析和行業預測

Amyotrophic Lateral Sclerosis Treatment Market By Drugs, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

2022年肌萎縮側索硬化症治療市場價值為6.6225億美元，預計2032年將達到10.3894億美元，2023年至2032年復合年增長率為4.6%

Amyotrophic Lateral Sclerosis Treatment Market-IMG1

肌萎縮側索硬化症 (ALS)，也稱為盧伽雷氏病，是一種影響大腦和脊髓神經細胞的進行性神經退行性疾病。ALS 逐漸破壞並殺死這些神經細胞，導致肌肉失去控制並最終癱瘓。ALS 的症狀通常始於手腳無力或僵硬，並逐漸擴散到身體的其他部位。其他症狀包括說話、吞嚥、呼吸困難以及肌肉痙攣或痙攣。目前 ALS 尚無治愈方法，治療主要集中在控制症狀和改善生活質量。

常用來治療肌萎縮性側索硬化症的藥物包括利魯唑、依達拉奉、苯丁酸鈉和牛磺迪奧。利魯唑的作用是抑制谷氨酸的釋放，谷氨酸是一種損害運動神經元的神經遞質，而依達拉奉是一種自由基清除劑，可以減少體內損害運動神經元的氧化應激。

推動全球肌萎縮側索硬化症治療市場增長的主要因素包括肌萎縮側索硬化症患病率的增加以及 ALS 新藥和治療方法的批准增加。隨著世界人口老齡化，肌萎縮側索硬化症的患病率預計將上升，從而導致對有助於控制症狀和減緩疾病進展的治療和藥物的需求增加。我在這裡。

另一個市場驅動因素是醫療保健專業人員、患者和護理人員對 ALS 的認識和理解不斷增強。ALS 研究的進步和醫療技術的進步增加了我們對 ALS 潛在機制和潛在治療靶點的了解。因此，基因療法和乾細胞療法等開發正在取得進展，預計市場在預測期內將會增長。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進者
      • 提高對 ALS 的認識和理解
      • 肌萎縮側索硬化症患病率增加
      • 政府和非政府組織的努力
    • 阻礙因素
      • 藥物副作用
    • 機會
      • 增加研發活動
  • COVID-19 市場影響分析

4 肌萎縮側索硬化症治療市場（按代理商）

  • 概述
    • 市場規模和預測
  • 利魯唑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 依達拉奉
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

5 肌萎縮側索硬化症治療市場（按類型）

  • 概述
    • 市場規模和預測
  • 散發性肌萎縮側索硬化症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 家族性肌萎縮側索硬化症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

6 肌萎縮側索硬化症治療市場（按分銷渠道）

  • 概述
    • 市場規模及預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7 肌萎縮側索硬化症治療市場（按地區）

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模/預測：按藥物分類
    • 市場規模/預測：按類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模/預測：按藥物分類
    • 市場規模/預測：按類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模/預測：按藥物分類
    • 市場規模/預測：按類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模/預測：按藥物分類
    • 市場規模/預測：按類型
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按藥物分類
      • 市場規模/預測：按類型
      • 市場規模和預測：按分銷渠道劃分

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第九章公司簡介

  • Amylyx Pharmaceuticals, Inc.
  • Aquestive Therapeutics, Inc.
  • Covis Pharma GmbH
  • Glenmark Pharmaceuticals Limited
  • ITALFARMACO S.p.A.
  • Mitsubishi Chemical Group Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Alkem Laboratories Ltd
  • Otsuka Pharmaceutical Co., Ltd.
Product Code: A10244

The amyotrophic lateral sclerosis treatment market valued for $662.25 million in 2022 and is estimated to reach $1,038.94 million by 2032, exhibiting a CAGR of 4.6% from 2023 to 2032.

Amyotrophic Lateral Sclerosis Treatment Market - IMG1

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS causes these nerve cells to gradually break down and die, which results in the loss of muscle control and eventual paralysis. The symptoms of ALS typically begin with muscle weakness or stiffness, often in the hands or feet, and gradually spread to other parts of the body. Other symptoms include difficulty speaking, swallowing, or breathing, as well as muscle cramps and twitching. There is currently no cure for ALS, and treatment mainly focuses on managing symptoms and improving the quality of life for people with the disease.

Some of the drugs that are commonly used to treat amyotrophic lateral sclerosis include Riluzole, Edaravone, and Sodium phenylbutyrate and taurursodio. Riluzole works by reducing the release of glutamate, a neurotransmitter that damage motor neurons and Edaravone is a free radical scavenger that works by reducing oxidative stress in the body, which damage the motor neurons.

The major factors that drive the growth of the global amyotrophic lateral sclerosis treatment market include, increase in prevalence of amyotrophic lateral sclerosis, and rise in approval of new drugs and therapies for ALS. The incidence of ALS is expected to rise, as the global population ages, leading to a growth in demand for treatments and therapies that may help to manage the symptoms and slow the progression of the disease.

Another market driver is the growth in awareness and understanding of ALS among healthcare professionals, patients, and caregivers. There is a greater understanding of the underlying mechanisms of ALS and potential targets for treatment with more research being done on the disease and advances in medical technology. This has led to the development of new therapies, such as gene therapies and stem cell treatments, which are expected to drive market growth during the forecast period.

In addition, regulatory frameworks and reimbursement policies may also impact the market for ALS treatments. The approval of new drugs and therapies by regulatory bodies, such as the U.S. FDA, may drive market growth by providing patients with access to new and innovative treatments. For instance, increase in pipeline products such as Tofersen, ANX005 and others for treating an amyotrophic lateral sclerosis which is anticipated to provide lucrative opportunities to the market players. Reimbursement policies that provide coverage for these treatments can also help to expand the market by making them more accessible and affordable for patients.

However, limited understanding of the disease, stringent regulatory process for approving new treatments for ALS, which can delay the availability of new therapies for patients and higher treatment may restrict the market growth.

The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, the market is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global amyotrophic lateral sclerosis treatment market are: Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. Key players operating in the market have adopted product approval, agreement, and product launch as their key strategies to expand their product portfolio. For instance, in January 2023, Amylyx Pharmaceuticals, Inc. announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm is expected to commercialize to regulatory review and approval of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amyotrophic lateral sclerosis treatment market analysis from 2022 to 2032 to identify the prevailing amyotrophic lateral sclerosis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the amyotrophic lateral sclerosis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global amyotrophic lateral sclerosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drugs

  • Riluzole
  • Edaravone
  • Others

By Type

  • Sporadic ALS
  • Familial ALS

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Alkem Laboratories Ltd
    • Amylyx Pharmaceuticals, Inc.
    • Aquestive Therapeutics, Inc.
    • Covis Pharma GmbH
    • Glenmark Pharmaceuticals Limited
    • ITALFARMACO S.p.A.
    • Mitsubishi Chemical Group Corporation
    • Otsuka Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in awareness and understanding of ALS
      • 3.4.1.2. Increase in prevalence of amyotrophic lateral sclerosis
      • 3.4.1.3. Initiatives by government and non-government organizations
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects of drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Riluzole
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Edaravone
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Sporadic ALS
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Familial ALS
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drugs
    • 7.2.3. Market size and forecast, by Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drugs
      • 7.2.5.1.3. Market size and forecast, by Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drugs
      • 7.2.5.2.3. Market size and forecast, by Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drugs
      • 7.2.5.3.3. Market size and forecast, by Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drugs
    • 7.3.3. Market size and forecast, by Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drugs
      • 7.3.5.1.3. Market size and forecast, by Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drugs
      • 7.3.5.2.3. Market size and forecast, by Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drugs
      • 7.3.5.3.3. Market size and forecast, by Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drugs
      • 7.3.5.4.3. Market size and forecast, by Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drugs
      • 7.3.5.5.3. Market size and forecast, by Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drugs
      • 7.3.5.6.3. Market size and forecast, by Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drugs
    • 7.4.3. Market size and forecast, by Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drugs
      • 7.4.5.1.3. Market size and forecast, by Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drugs
      • 7.4.5.2.3. Market size and forecast, by Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drugs
      • 7.4.5.3.3. Market size and forecast, by Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drugs
      • 7.4.5.4.3. Market size and forecast, by Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drugs
      • 7.4.5.5.3. Market size and forecast, by Type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drugs
      • 7.4.5.6.3. Market size and forecast, by Type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drugs
    • 7.5.3. Market size and forecast, by Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drugs
      • 7.5.5.1.3. Market size and forecast, by Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drugs
      • 7.5.5.2.3. Market size and forecast, by Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drugs
      • 7.5.5.3.3. Market size and forecast, by Type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drugs
      • 7.5.5.4.3. Market size and forecast, by Type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Amylyx Pharmaceuticals, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Aquestive Therapeutics, Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Covis Pharma GmbH
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Glenmark Pharmaceuticals Limited
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. ITALFARMACO S.p.A.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Mitsubishi Chemical Group Corporation
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Viatris Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Alkem Laboratories Ltd
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Otsuka Pharmaceutical Co., Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 02. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 06. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 21. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 37. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 40. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 56. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 62. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. AMYLYX PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 87. AMYLYX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 88. AMYLYX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 89. AMYLYX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 90. AMYLYX PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 91. AQUESTIVE THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 92. AQUESTIVE THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 93. AQUESTIVE THERAPEUTICS, INC.: PRODUCT SEGMENTS
  • TABLE 94. AQUESTIVE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 95. COVIS PHARMA GMBH: KEY EXECUTIVES
  • TABLE 96. COVIS PHARMA GMBH: COMPANY SNAPSHOT
  • TABLE 97. COVIS PHARMA GMBH: PRODUCT SEGMENTS
  • TABLE 98. COVIS PHARMA GMBH: PRODUCT PORTFOLIO
  • TABLE 99. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 100. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 101. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 102. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 103. ITALFARMACO S.P.A.: KEY EXECUTIVES
  • TABLE 104. ITALFARMACO S.P.A.: COMPANY SNAPSHOT
  • TABLE 105. ITALFARMACO S.P.A.: PRODUCT SEGMENTS
  • TABLE 106. ITALFARMACO S.P.A.: PRODUCT PORTFOLIO
  • TABLE 107. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY EXECUTIVES
  • TABLE 108. MITSUBISHI CHEMICAL GROUP CORPORATION: COMPANY SNAPSHOT
  • TABLE 109. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT SEGMENTS
  • TABLE 110. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT PORTFOLIO
  • TABLE 111. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY STRATERGIES
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 116. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 120. ALKEM LABORATORIES LTD: KEY EXECUTIVES
  • TABLE 121. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 122. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
  • TABLE 123. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 124. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 125. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 126. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 127. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALAMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET
  • FIGURE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET BY REGION, 2022
  • FIGURE 22. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. AMYLYX PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. AQUESTIVE THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AQUESTIVE THERAPEUTICS, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. MITSUBISHI CHEMICAL GROUP CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. MITSUBISHI CHEMICAL GROUP CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)